Online inquiry

IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4790MR)

This product GTTS-WQ4790MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets DPP4 gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001379604.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1803
UniProt ID P27487
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4790MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10553MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ8859MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ8995MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ14952MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ6929MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ9397MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Iomab-B
GTTS-WQ6309MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ174MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 1-26/3-67
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW